Reteplase biosimilar - Reliance Life Sciences

Drug Profile

Reteplase biosimilar - Reliance Life Sciences

Alternative Names: MiRel; R TPR 004

Latest Information Update: 16 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Reliance Life Sciences
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • No development reported Stroke

Most Recent Events

  • 16 Dec 2015 No development reported - Phase-II for Stroke in India (IV)
  • 06 May 2013 Phase-II clinical trials in Stroke in India (IV)
  • 31 Dec 2009 Launched for Myocardial infarction in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top